Congressi & Meeting, Dicembre 2002 - Gimmoc.it

5. Craig WA. Pharmacokinetic/pharmacodynamic
parameters: rationale for antibacterial dosing of
mice and men. Clin Infect Dis. 1998; 26:1-10.
6. Klepser ME, Marangos MN, Patel KB, Nicolau
DP, Quintiliani R, Nightingale CH. Clinical
pharmacokinetics of newer cephalosporins.
Clin Pharmacokinet. 1995; 28(5):361-384.
7. Lode H, Fassbender M, Schaberg T, Borner
K, Koeppe P. Comparative pharmacokinetics
of the new oral cephalosporins. Drugs. 1994; 47
(Suppl 3):10-19.
8. Periti P, Mazzei T, Mini E, Novelli A. Il
ceftibuten, farmacologia clinica e chemioterapia.
Farmaci & Terapia. 1992; IX (Suppl. 1).
9. Perry CM, Brogden RN. Cefuroxime axetil. A
review of its antibacterial activity, pharmacokinetic
properties and therapeutic efficacy. Drugs.
1996;52:125-158.
10. Appelbaum PC, Hunter PA. The fluoroquinolone
antibacterials: past, present and future
perspectives. Int J Antimicrob Agents.
2000; 16(1): 5-15.
11. Peterson LR. Quinolone molecular structureactivity
relationships: what we have learned
about improving antimicrobial activity. Clin Infect
Dis. 2001; 33 (Suppl 3):S180-S186.
12. von Rosenstiel N, Adam D. Quinolone antibacterials.
An update of their pharmacology
and therapeutic use. Drugs. 1994; 47(6):872-
901.
13. Mazzei T, Novelli A, Reali EF, Balocchini E,
Boni S, De Stasio A, Patrignani G, Lusini C,
Periti P. Farmacocinetica e penetrazione tissutale
della oflossocina. Farmaci & Terapia. 1987;
4 (4): 244-249.
14. Novelli A, Cassetta MI, Fallani S, Periti P.
Clinical pharmacokinetics and tissue penetration
of ciprofloxacin after a single or multiple
oral dose of 250 or 500 mg. Eur J Clin Microbiol
Infect Dis. 1991a; 20: 367-369.
15. Novelli A, Fallani S, Cassetta MI, Periti P.
Clinical pharmacokinetics, tissue penetration
and bioavailability of pefloxacin after a single
i.v. or oral dose of 800 mg. Eur J Clin Microbiol
Infect Dis. 1991b; 20: 604-606.
16. Preston SL, Drusano GL, Berman AL,
Fowler CL, Chow AT, Dornseif B, Reichl V,
Natarajan J, Corrado M. Pharmacodynamics
of levofloxacin: a new paradigm for early clinical
trials. JAMA.1998; 279(2):125-129.
17. Schentag JJ. Clinical pharmacology of the fluoroquinolones:
studies in human dynamic/kinetic
models. Clin Infect Dis. 2000;31 (Suppl
2):S40-S44.
18. Ball P. Future of the quinolones. Semin Respir
Infect. 2001; 16(3):215-224.
19. Fish DN. Fluoroquinolone adverse effects and
drug interactions. Pharmacotherapy. 2001;
21(10 Pt 2):253S-272S.
20. Brumfitt W, Hamilton-Miller JM. Combinations
of sulphonamides with diamino-pyrimidines:
how, when and why? J Chemother. 1995;
7(2):136-139.
21. Patel SS, Balfour JA, Bryson HM. Fosfomycin
tromethamine. A review of its antibacterial activity,
pharmacokinetic properties and therapeutic
efficacy as a single-dose oral treatment for acute
uncomplicated lower urinary tract infections.
Drugs. 1997; 53(4):637-656.
22. Fuchs PC, Barry AL, Brown SD. Fosfomycin
tromethamine susceptibility of outpatient urine
isolates of Escherichia coli and Enterococcus
faecalis from ten North American medical centres
by three methods. J Antimicrob Chemother.
1999; 43(1):137-140.
23. Garcia-Rodriguez JA, Trujillano Martin I,
Baquero F, Cisterna R, Gobernado M,
Linares F, Martin-Luengo F, Piedrola G. In
vitro activity of fosfomycin trometamol against
pathogens from urinary tract infections: a Spanish
multicenter study. J Chemother. 1997;
9(6):394-402.
24. Novelli A, Periti E. How to select a drug for the
treatment of bacteriuria in pregnancy. New
trends Gynecol Obstet. 1990; 6(3-4): 189-193.
25. Krcmery S, Hromec J, Demesova D. Treatment
of lower urinary tract infection in pregnancy.
Int J Antimicrob Agents. 2001; 17(4):279-
282.
GIMMOC Vol. VI C&M 1, 2002
Congressi
& Meeting
UTI NON COMPLICATE / EXTENDED ABSTRACTS
19